nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Lisinopril—dilated cardiomyopathy	0.307	0.532	CbGbCtD
Tolvaptan—ABCB1—Spironolactone—dilated cardiomyopathy	0.27	0.468	CbGbCtD
Tolvaptan—Polydipsia—Furosemide—dilated cardiomyopathy	0.0195	0.0707	CcSEcCtD
Tolvaptan—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.0109	0.0396	CcSEcCtD
Tolvaptan—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00652	0.0236	CcSEcCtD
Tolvaptan—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00616	0.0223	CcSEcCtD
Tolvaptan—Renal failure—Spironolactone—dilated cardiomyopathy	0.00611	0.0222	CcSEcCtD
Tolvaptan—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.00593	0.0215	CcSEcCtD
Tolvaptan—Urine output increased—Furosemide—dilated cardiomyopathy	0.00547	0.0198	CcSEcCtD
Tolvaptan—Polyuria—Furosemide—dilated cardiomyopathy	0.005	0.0181	CcSEcCtD
Tolvaptan—AVPR2—Arf6 trafficking events—AGTR1—dilated cardiomyopathy	0.00465	0.0317	CbGpPWpGaD
Tolvaptan—Thirst—Furosemide—dilated cardiomyopathy	0.00461	0.0167	CcSEcCtD
Tolvaptan—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00454	0.0164	CcSEcCtD
Tolvaptan—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00451	0.0163	CcSEcCtD
Tolvaptan—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00446	0.0162	CcSEcCtD
Tolvaptan—AVPR2—Arf6 trafficking events—ADRB2—dilated cardiomyopathy	0.00441	0.0301	CbGpPWpGaD
Tolvaptan—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00441	0.016	CcSEcCtD
Tolvaptan—Malaise—Spironolactone—dilated cardiomyopathy	0.00438	0.0159	CcSEcCtD
Tolvaptan—AVPR2—Arf6 trafficking events—ITGB1—dilated cardiomyopathy	0.00426	0.029	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.00423	0.0289	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0042	0.0287	CbGpPWpGaD
Tolvaptan—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00411	0.0149	CcSEcCtD
Tolvaptan—Discomfort—Spironolactone—dilated cardiomyopathy	0.00409	0.0148	CcSEcCtD
Tolvaptan—Dehydration—Furosemide—dilated cardiomyopathy	0.00408	0.0148	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00401	0.0145	CcSEcCtD
Tolvaptan—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00397	0.0144	CcSEcCtD
Tolvaptan—AVPR1A—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00394	0.0269	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00391	0.0267	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00371	0.0253	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00368	0.0251	CbGpPWpGaD
Tolvaptan—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00351	0.0127	CcSEcCtD
Tolvaptan—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00346	0.0125	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00342	0.0124	CcSEcCtD
Tolvaptan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00342	0.0124	CcSEcCtD
Tolvaptan—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00338	0.0122	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00336	0.0122	CcSEcCtD
Tolvaptan—Renal failure—Furosemide—dilated cardiomyopathy	0.00333	0.0121	CcSEcCtD
Tolvaptan—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00331	0.012	CcSEcCtD
Tolvaptan—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00327	0.0118	CcSEcCtD
Tolvaptan—AVPR1A—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00325	0.0222	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00323	0.0221	CbGpPWpGaD
Tolvaptan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00314	0.0114	CcSEcCtD
Tolvaptan—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00309	0.0112	CcSEcCtD
Tolvaptan—Dehydration—Lisinopril—dilated cardiomyopathy	0.00306	0.0111	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00301	0.0109	CcSEcCtD
Tolvaptan—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.003	0.0109	CcSEcCtD
Tolvaptan—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00298	0.0108	CcSEcCtD
Tolvaptan—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00298	0.0108	CcSEcCtD
Tolvaptan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00292	0.0106	CcSEcCtD
Tolvaptan—Pruritus—Spironolactone—dilated cardiomyopathy	0.00281	0.0102	CcSEcCtD
Tolvaptan—Angiopathy—Furosemide—dilated cardiomyopathy	0.00276	0.00999	CcSEcCtD
Tolvaptan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00274	0.00994	CcSEcCtD
Tolvaptan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00271	0.00984	CcSEcCtD
Tolvaptan—Malnutrition—Furosemide—dilated cardiomyopathy	0.00264	0.00958	CcSEcCtD
Tolvaptan—Dizziness—Spironolactone—dilated cardiomyopathy	0.00262	0.00951	CcSEcCtD
Tolvaptan—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00259	0.00938	CcSEcCtD
Tolvaptan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00257	0.00931	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.0025	0.0171	CbGpPWpGaD
Tolvaptan—Renal failure—Lisinopril—dilated cardiomyopathy	0.0025	0.00904	CcSEcCtD
Tolvaptan—Headache—Spironolactone—dilated cardiomyopathy	0.00248	0.00901	CcSEcCtD
Tolvaptan—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00245	0.0167	CbGpPWpGaD
Tolvaptan—Nausea—Spironolactone—dilated cardiomyopathy	0.00236	0.00854	CcSEcCtD
Tolvaptan—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00225	0.00816	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00224	0.0081	CcSEcCtD
Tolvaptan—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00223	0.0081	CcSEcCtD
Tolvaptan—Dry mouth—Furosemide—dilated cardiomyopathy	0.0022	0.00798	CcSEcCtD
Tolvaptan—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00216	0.00782	CcSEcCtD
Tolvaptan—Shock—Furosemide—dilated cardiomyopathy	0.00212	0.00769	CcSEcCtD
Tolvaptan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00212	0.00767	CcSEcCtD
Tolvaptan—Skin disorder—Furosemide—dilated cardiomyopathy	0.0021	0.0076	CcSEcCtD
Tolvaptan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00207	0.00749	CcSEcCtD
Tolvaptan—Anorexia—Furosemide—dilated cardiomyopathy	0.00206	0.00745	CcSEcCtD
Tolvaptan—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00205	0.00744	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.00203	0.0138	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00199	0.0136	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00199	0.0136	CbGpPWpGaD
Tolvaptan—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00198	0.00719	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00198	0.0135	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00198	0.0135	CbGpPWpGaD
Tolvaptan—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00194	0.00704	CcSEcCtD
Tolvaptan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00188	0.0068	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00186	0.00675	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00185	0.0126	CbGpPWpGaD
Tolvaptan—Constipation—Furosemide—dilated cardiomyopathy	0.00185	0.00669	CcSEcCtD
Tolvaptan—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00184	0.00667	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00184	0.0125	CbGpPWpGaD
Tolvaptan—Malaise—Lisinopril—dilated cardiomyopathy	0.00179	0.00648	CcSEcCtD
Tolvaptan—Syncope—Lisinopril—dilated cardiomyopathy	0.00178	0.00645	CcSEcCtD
Tolvaptan—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00178	0.00644	CcSEcCtD
Tolvaptan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00174	0.00632	CcSEcCtD
Tolvaptan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00171	0.00618	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00168	0.00608	CcSEcCtD
Tolvaptan—Discomfort—Lisinopril—dilated cardiomyopathy	0.00167	0.00605	CcSEcCtD
Tolvaptan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00165	0.00599	CcSEcCtD
Tolvaptan—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00162	0.00587	CcSEcCtD
Tolvaptan—Shock—Lisinopril—dilated cardiomyopathy	0.00159	0.00577	CcSEcCtD
Tolvaptan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00159	0.00576	CcSEcCtD
Tolvaptan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00157	0.0057	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00156	0.0106	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00155	0.0106	CbGpPWpGaD
Tolvaptan—Asthenia—Furosemide—dilated cardiomyopathy	0.00155	0.00561	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00155	0.0106	CbGpPWpGaD
Tolvaptan—Anorexia—Lisinopril—dilated cardiomyopathy	0.00154	0.00559	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00153	0.0104	CbGpPWpGaD
Tolvaptan—Pruritus—Furosemide—dilated cardiomyopathy	0.00153	0.00553	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00152	0.0104	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00149	0.0102	CbGpPWpGaD
Tolvaptan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00148	0.00535	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00145	0.00989	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00145	0.00987	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00145	0.00987	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00144	0.00982	CbGpPWpGaD
Tolvaptan—Dizziness—Furosemide—dilated cardiomyopathy	0.00143	0.00517	CcSEcCtD
Tolvaptan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00141	0.0051	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.0014	0.00958	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.0014	0.00507	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00139	0.00951	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00139	0.00946	CbGpPWpGaD
Tolvaptan—Constipation—Lisinopril—dilated cardiomyopathy	0.00138	0.00502	CcSEcCtD
Tolvaptan—Headache—Furosemide—dilated cardiomyopathy	0.00135	0.0049	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00135	0.00918	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00134	0.00911	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00134	0.00911	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00133	0.00484	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00133	0.00905	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00133	0.00905	CbGpPWpGaD
Tolvaptan—Nausea—Furosemide—dilated cardiomyopathy	0.00128	0.00465	CcSEcCtD
Tolvaptan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00128	0.00464	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00124	0.00847	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00123	0.00841	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.0012	0.0082	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.0012	0.00818	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00119	0.00814	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00119	0.00432	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00119	0.00812	CbGpPWpGaD
Tolvaptan—Asthenia—Lisinopril—dilated cardiomyopathy	0.00116	0.00421	CcSEcCtD
Tolvaptan—Pruritus—Lisinopril—dilated cardiomyopathy	0.00115	0.00415	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00114	0.00776	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00113	0.0077	CbGpPWpGaD
Tolvaptan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00111	0.00401	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00109	0.00744	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00108	0.00735	CbGpPWpGaD
Tolvaptan—Dizziness—Lisinopril—dilated cardiomyopathy	0.00107	0.00388	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00107	0.0073	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00103	0.00701	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00102	0.00696	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00102	0.00694	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00102	0.00694	CbGpPWpGaD
Tolvaptan—Headache—Lisinopril—dilated cardiomyopathy	0.00101	0.00368	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00101	0.00689	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00101	0.00689	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000976	0.00666	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000974	0.00665	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000967	0.0066	CbGpPWpGaD
Tolvaptan—Nausea—Lisinopril—dilated cardiomyopathy	0.000962	0.00349	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000945	0.00645	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000939	0.0064	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000916	0.00625	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000909	0.0062	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000782	0.00534	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000776	0.0053	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000742	0.00506	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000736	0.00503	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000723	0.00493	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000717	0.00489	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000694	0.00474	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000677	0.00462	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000584	0.00399	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000575	0.00392	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000575	0.00392	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000571	0.00389	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000571	0.00389	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00055	0.00375	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000546	0.00373	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000534	0.00365	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00053	0.00362	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000522	0.00356	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000522	0.00356	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000518	0.00354	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000518	0.00354	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000517	0.00353	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000514	0.00351	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.00049	0.00334	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000485	0.00331	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000482	0.00329	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00047	0.00321	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000466	0.00318	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000464	0.00317	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000455	0.00311	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000442	0.00302	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000439	0.00299	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000439	0.00299	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000419	0.00286	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000416	0.00284	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000401	0.00274	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000398	0.00272	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000381	0.0026	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000378	0.00258	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000347	0.00237	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000345	0.00235	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000325	0.00222	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000323	0.0022	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000311	0.00212	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000309	0.00211	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000308	0.0021	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000308	0.0021	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000306	0.00209	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000306	0.00209	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000296	0.00202	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000293	0.002	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000293	0.002	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000287	0.00196	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000285	0.00194	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000283	0.00193	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000282	0.00193	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00028	0.00191	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000278	0.00189	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000276	0.00188	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000276	0.00188	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000276	0.00188	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000256	0.00175	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000237	0.00162	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000235	0.00161	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000225	0.00153	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000225	0.00153	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000223	0.00152	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000217	0.00148	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000212	0.00145	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000196	0.00134	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000195	0.00133	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000193	0.00132	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000192	0.00131	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000186	0.00127	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000186	0.00127	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000175	0.0012	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000175	0.00119	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000173	0.00118	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000167	0.00114	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGT—dilated cardiomyopathy	0.000166	0.00113	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000158	0.00108	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000141	0.000961	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000134	0.000917	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000133	0.00091	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000116	0.00079	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000115	0.000784	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000115	0.000783	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000108	0.000736	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	9.76e-05	0.000666	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	9.65e-05	0.000659	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	9.19e-05	0.000627	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	7.94e-05	0.000542	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EGFR—dilated cardiomyopathy	7.88e-05	0.000538	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.59e-05	0.000381	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	4.3e-05	0.000294	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CD36—dilated cardiomyopathy	4.19e-05	0.000286	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—AGT—dilated cardiomyopathy	3.77e-05	0.000257	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.65e-05	0.000181	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.58e-05	0.000176	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.32e-05	0.000159	CbGpPWpGaD
